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Abstract
We investigated the independent effects of HIV-1 ’’target not detected’’ measurements versus those that were detectable
but below the limit of quantification by Taqman RT-PCR assay on subsequent viral rebound as there are conflicting data
regarding the clinical implications of arbitrary or isolated low-level viremia. Cox proportional hazard regression modeling
was used to investigate the independent effects of the first HIV-1 load measurement after introduction of the Taqman RT-
PCR assay (time-point 0 [T0]), pre-T0 viral loads, CD4 T cell count, race/ethnicity, gender, age and NNRTI use on risk of a
confirmed VL .50, .200, .400 and .1000 copies/mL at 22 months follow-up in analyses of all patients and propensity-
matched baseline cohorts. 778 patients had a viral load that was either not detected by RT-PCR (N=596) or detectable, but
below the limit of quantification (N=182) at T0. Detectable viremia, lower T0 CD4 count, decreased age, and having
detectable or unknown VL within a year prior to T0 were each associated with viral rebound to .50, .200 and .400
copies/mL. Overall failure rates were low and ,5.5% of all patients had confirmed VL .1000 copies/mL. A majority of
patients with rebound .200 copies/mL subsequently re-suppressed (28 of 53). A detectable VL ,48 copies/mL was
independently and significantly associated with subsequent viral rebound, and is cause for clinical concern.
Citation: Henrich TJ, Wood BR, Kuritzkes DR (2012) Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load ,48 Copies/
mL. PLoS ONE 7(11): e50065. doi:10.1371/journal.pone.0050065
Editor: Mark Wainberg, McGill University AIDS Centre, Canada
Received August 2, 2012; Accepted October 18, 2012; Published November 15, 2012
Copyright:  2012 Henrich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the NIH/NIAID K23AI098480 to T.J.H.; UM1 AI068636 to D.R.K. through a Virology Specialty Laboratory subcontract from the
AIDS Clinical Trials Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: D.R.K. is a consultant to and has received honoraria from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline,
InnoVirVax, Koronis, Merck, Roche, Roxane, Sangamo, ViiV, ViroStatics and VIRxSYS; he has received grant support from Gilead and Merck, and speaking honoraria
from Gilead and Roche. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the
PLOS ONE policies on sharing data and materials.
* E-mail: thenrich@partners.org
. These authors contributed equally to this work.
Introduction
Monitoring the response to antiretroviral therapy relies upon
measurements of HIV-1 RNA, with the goal to achieve virologic
suppression, defined as a level below the limit of detection of the
assay [1]. As assays have become more sensitive, the frequency of
detectable HIV-1 RNA at low levels and below the quantifiable
range of these tests has become more common but the clinical
significance of such results is unclear [2,3,4,5,6,7]. In particular,
data regarding the clinical implications of a detectable plasma
HIV-1 RNA below the quantifiable limit of 50 copies/mL (very
low-level viremia, VLLV) are mixed. Two studies have shown a
significant association between sporadic VLLV measurements and
viral rebound to above 50 or 400 copies/mL [8,9]. However, two
additional studies did not find significant associations between
VLLV and subsequent rebound [10,11]. The methods for
quantifying viral loads (VL) differed between these studies, and
confounding may have been introduced, as patient characteristics,
such as CD4 T cell counts, time of prior virologic control and the
use of NNRTI-based regimens differed between baseline compar-
ator groups [8,10,11].
These mixed findings leave clinicians with a conundrum when
faced with plasma HIV-1 RNA results that fall into the detectable
but not quantifiable range: should such a finding prompt a change
of therapy, closer monitoring, or no action at all? Further study is
warranted to understand fully the clinical implications of VLLV in
various populations and in individuals who rebound with higher
viral loads. We investigated the independent effects of ’’target not
detected’’ measurements versus those that were detectable but
below the limit of quantification using the Roche Cobas Taqman
RT-PCR assay on risk of virologic rebound in patients followed at
two academic medical centers, and described virologic outcomes
of patients experiencing rebound.
Methods
The Partners Healthcare Human Research Committee re-
viewed and approved this study. The requirement to obtain
informed consent from each individual was waived by the
institutional review board as the study was limited to review of
existing medical records.
Data from electronic medical records of HIV-1-infected patients
on treatment at or after the time the Roche Cobas Taqman RT-
PCR assay v.1 was introduced into use were collected at two
academic medical centers in Boston, Massachusetts. One institu-
tion changed from the Versant bDNA assay (limit of detection
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second institution changed from the Cobas Amplicor assay (limit
of detection =50 copies/mL) to the Cobas Taqman assay in
December, 2009. Patient information was collected at all available
time-points following the first viral load (VL) result obtained with
the new Taqman assay (time-point 0 [T0]). Information collected
included patient demographics, CD4 T-cell count, VL, and
antiretroviral regimen, and if all known pre-Taqman VL assays
were below the limit of detection (,assay threshold) one year prior
to T0. Patients included in the analysis were selected based on the
Taqman assay result at T0: those with VL that was detectable but
below the limit of quantification (,48 copies/mL; BLQ), and
those with VL reported as target not detected (TND). Subjects
were included in the analysis only if they had a minimum of two
VL measurements after T0.
Baseline characteristics for the TND and BLQ groups were
compared using Fisher’s exact test for gender and use of non-
nucleoside reverse transcriptase inhibitor (NNRTI) therapy, x
2 test
for race/ethnicity, and Mann-Whitney U test for age and CD4 T-
cell counts. Cox proportional hazard regression modeling was used
to investigate the independent effects of the first VL measurement
and other demographic and laboratory covariates after introduc-
tion of the Taqman RT-PCR assay on the risk of virologic
rebound. Rebound groups were defined for study purposes as
having a confirmed VL .50, .200, .400 or .1000 copies/mL
(or a single VL above the cutoff value if this was the last available
determination) with follow-up censored at 22 months. A confirmed
VL was defined as a result with at least one consecutive
measurement greater than the VL threshold value. The study
period was determined by the mean length of follow-up and
availability of laboratory data. Patient demographics, CD4 T-cell
count at T0, NNRTI use, VL group at T0, and known VL ,
assay threshold 1 year prior to T0 were included in the Cox
regression model. The regression was repeated using a viral
rebound definition excluding a single VL above the cutoff value at
the last available determination. A second hazard analysis was
performed to determine the effects of T0 viral load group using a
propensity score matched TND comparator cohort (1:2 BLQ to
TND). Propensity scores were calculated by the nearest neighbor
method including all study variables as covariates.
Additional clinical information was obtained from the records of
patients with confirmed or last VL .200 copies/mL, including
whether or not resistance testing was requested because of
virologic rebound, resistance test results, changes in antiretroviral
drugs at the time of rebound, and whether virologic suppression
was re-established (defined as a confirmed or last VL of ,50
copies/mL) after initial rebound. All statistical analyses were
performed with SPSS vs. 20 and R Essentials.
Results
A total of 778 patients had a VL that was TND (N=596) or
BLQ (N=182) at T0. Baseline CD4 cell counts were significantly
lower in the BLQ group (Table 1). The propensity analysis
incorporated 540 patients (propensity matched TND=360,
BLQ=182). Propensity matching reduced standardized differenc-
es for all covariates to near zero (all between -0.05 to 0.05), with no
significant differences between baseline characteristics in the BLQ
or matched TND groups (Table 1).
During 22 months of follow-up, 66 patients in the TND group
(11.4%) and 60 in the BLQ group (33%) had a confirmed or last
VL .50 copies/mL. Thirty-two (5.4%) and 21 (11.5%) of patients
in the TND and BLQ groups experienced rebound to a VL .200
copies/mL, whereas 26 (4.4%) and 18 (9.9%), respectively,
rebounded to .400 copies/mL. Only 20 of patients in the TND
group (3.4%) and 10 in the BLQ group (5.5%) experienced viral
rebound .1000 copies/mL. A similar percentage of patients
experienced viral rebound .50, .200, .400, and .1000 copies/
mL from the propensity-matched TND cohort when compared to
the unmatched TND population (12.2%, 5.8%, 4.7%, and 3.9%,
respectively).
Table 2 shows results of the Cox proportional hazard regression
analysis. Factors including a VL BLQ at T0, lower CD4 count,
younger age, and known detectable viral load prior to T0 by the
older VL assays were independently associated with a subsequent
confirmed VL .50, .200 and .400 copies/mL for all patients.
BLQ VL at T0 was also associated with a subsequent confirmed
VL .50, .200, and .400 copies/mL in the propensity-matched
cohort study. Of note, the clinical laboratory made no distinction
between TND and BLQ prior to the Taqman assay roll-out at T0,
but clinicians had subsequent access to the BLQ result.
Factors including a VL BLQ at T0, lower CD4 count, and
known detectable viral load prior to T0 by the older VL assays
were independently associated with a subsequent confirmed VL
.50, .200 and .400 copies/mL from Cox regression analysis of
all patients defining viral rebound as only a confirmed, consecutive
VL above the cutoff value. Younger age was also associated with
VL.200 and .400 copies/mL (all P,0.05). Only lower CD4
count and known detectable viral load prior to T0 were
independently associated with viral rebound .1000 copies/mL.
Of the 53 patients from the entire population who experienced
viral rebound to .200 copies/mL, 55% re-suppressed to ,50
copies/mL. Of the 24 patients that did not resuppress, 10 had
persistent VL .200, 5 had persistent LLVL .50 but ,200 and 9
had no further VL info available. Of note, 26% of patients were
receiving NNRTI based therapy at the time of viral rebound, and
30% of patients experiencing rebound to .200 copies/mL
underwent a change in ART. Interpretable results were obtained
from 22 of 34 genotypic resistance tests attempted. Nine of the 22
viral genotypes showed evidence of drug resistance, including 6
with NNRTI resistance. The median viral load at the time of
failure for the 9 patients with resistance was higher than for the 13
patients without measurable resistance (1863 versus 45294 copies/
mL, P=0.006). All 9 patients with documented drug resistance
changed antiretroviral regimens, of whom 7 subsequently re-
suppressed.
Discussion
A better understanding of the mechanisms and clinical
importance of residual viremia is needed as newer, more sensitive
assays are implemented. We show that viral load measurements
that are detectable but ,48 copies/mL independently predicted a
higher risk of virologic rebound to .50, .200 and .400 copies/
mL but ,1000 copies/mL when compared to undetectable
viremia (i.e., TND).The strongest predictor of viral rebound was
having quantifiable or unknown viral loads within the year prior to
rollout of the ultrasensitive Taqman assay; lower CD4 count at
baseline was also a strong predictor of rebound. Although power
to detect small differences between viral rebound at higher VL
copy numbers was lacking, a higher proportion of patients within
the T0 VL BLQ group experienced rebound .1000 copies/mL.
As a result, detectable but unquantifiable viral load measurements
are cause for concern.
Prior studies that examined the relationship between VLLV and
subsequent virologic rebound or failure have given mixed results.
For example, a single VLLV was associated with subsequent viral
rebound to .50 or 400 copies/mL at 12 to18 months in one study
Low-Level Viremia and Virologic Rebound
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and length of undetectable viremia or treatment duration prior to
the baseline VL may have introduced bias into the study, even
when adjusted for covariates in Cox regression modeling. When
our TND group was propensity-matched to the BLQ group by all
baseline variables, the significant association between VLLV and
virologic rebound remained. Three additional studies using a
cutoff of 50 copies/mL yielded conflicting results [9,10,11]. One
study identified an increased risk of virologic rebound over
12 months when comparing patients with VL ,3 copies/mL to
those with VL of 3 to 50 copies/mL [9], but two other studies
found no significant increase in VLLV and subsequent virological
failure [10,11].
Previous studies that identified significant positive associations
between VLLV and virologic rebound utilized the Abbot
RealTime PCR assay for VL testing. We identified a similar
association when VL testing was performed using the Roche
Cobas Taqman assay v.1. A higher frequency of low-level viral
Table 1. Baseline (T0) Study Population Characteristics.
Viral Load at T0
Target Not Detected ,48 copies/mL P
Whole population, N=778
Months (median) of follow-up post T0 18.8 20.0 .821
# of VL measurements (median) post T0 5 5 .56
Patients with known VL , assay threshold 1 year prior to T0 354 (59.4) 98 (53.8) .198
T0 CD4 count (median), cells/mm
3a 581 500 .003
Age (median years) 48.5 49.0 .431
Gender
Male 460 (77.2)
b 152 (83.5) .079
Female 136 (22.8) 30 (16.5)
Race/Ethnicity
White 350 (58.7) 106 (58.2) .577
Black 133 (22.3) 48 (26.4)
Hispanic 85 (14.3) 21 (11.5)
Other/ not reported 28 (4.7) 7 (3.8)
Antiretroviral Regimen
NNRTI-based 268 (45.0) 75 (41.2) .394
Non NNRTI-based
c 328 (55.0) 107 (58.8)
Propensity score-matched, N=540
d
Months (median) of follow-up post T0 19.8 20.0 .796
# of VL measurements (median) post T0 5 5 .485
Patients with known VL , assay threshold 1 year prior to T0 203 (56.4) 98 (54.4) .713
T0 CD4 count (median), cells/mm
3 540 500
e .468
Age (median years) 49 49
Gender
Male 305 (84.7) 150 (83.3) .707
Female 55 (15.3) 30 (17.7)
Race/Ethnicity
White 224 (62.2) 104 (57.8) .245
Black 69 (19.2) 48 (26.7)
Hispanic 51 (14.2) 21 (11.7)
Other/ not reported 16 (4.4) 7 (3.9)
Antiretroviral Regimen
NNRTI-based 151 (41.9) 73 (40.6) .782
Non NNRTI-based 209 (58.1) 107 (59.4)
Abbreviations: T0, time of first viral load result using the ultrasensitive Taqman assay (study entry); TND, target not detected; NNRTI, non-nucleoside reverse
transcriptase inhibitor.
a4 missing values, N=774.
bNumber and percent within T0 viral load group.
cIncludes protease inhibitor, integrase inhibitor-based and other regimens.
dIncludes 180 subjects with VL ,48 copies, and 360 subjects with undetectable VL propensity score-matched to the ,48 group.
eMean CD4 counts were identical after propensity matching.
doi:10.1371/journal.pone.0050065.t001
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quantification platforms has been described [3], but the Taqman
assay v.1 demonstrated similar performance to the Abbot
RealTime in a recent, large comparator study [12]. Version 1 of
the Taqman assay has been superseded by v.2 [6], but our findings
are particularly relevant given that associations between VLLV
and viral rebound have now been identified in studies incorpo-
rating different VL quantification methods.
A majority of patients (53%) with viral rebound to .200
copies/mL in our study resuppressed, even though less than a
third of patients changed ART regimens. A previous study showed
that low-level viremia appeared to be transient, with 40% of
patients reverting to complete suppression over time [10]. By
contrast, patients with persistent low-level viremia .50 copies/mL
experience higher rates of virologic failure .1000 copies/mL and
immune activation, and may be at risk of developing antiviral
resistance [13,14].
This study was limited by information available from medical
record review. Reliable information regarding CD4 T cell count
nadirs, duration of ART and suppressed viremia prior to T0 were
not available from the medical records, as patients either presented
to care already on therapy or had been followed intermittently at
facilities outside of our hospital network. As a result, survivor or
other bias may have been introduced into the analyses. Our study
incorporated the longest follow-up time used in recent studies of
VLLV and was unique in the use of propensity score-matching to
reduce standardized differences between baseline variables and
investigation of viral rebound at higher viral loads (e.g. .1000
copies/mL) [8,9,10].
In conclusion, our finding that VLLV is associated with a
greater risk of subsequent viral rebound is a cause for concern, but
the implications for clinical management are uncertain. Studies in
larger cohorts are needed to answer important clinical questions
regarding the potential increased costs of more frequent VL
monitoring or switching to more expensive or less well-tolerated
2
nd and 3
rd line regimens that may result from lowering VL cutoffs
that define full viral suppression [15,16].
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